Christopher R Kelsey
Overview
Explore the profile of Christopher R Kelsey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tseng Y, Stevenson P, Nguyen B, Li D, Lee D, Paydar I, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(5):1237-1247.
PMID: 39549763
Purpose: The presence of MYC and BCL2 translocations (ie, double-hit lymphoma, DHL) in large B-cell lymphoma (LBCL) is associated with reduced chemosensitivity, but less is known on its impact on...
2.
Hughes R, Razavian N, Shenker R, Kelsey C, Smith S, DAgostino Jr R, et al.
Adv Radiat Oncol
. 2024 Mar;
9(5):101450.
PMID: 38550369
Purpose: The role of consolidative radiation therapy (RT) in patients with advanced Hodgkin lymphoma with initial bulk is unclear. GITIL/FIL HD0607 and FIL HD0801, 2 randomized controlled trials with similar...
3.
Rankine L, Lu J, Wang Z, Kelsey C, Marks L, Das S, et al.
Int J Radiat Oncol Biol Phys
. 2024 Mar;
120(1):216-228.
PMID: 38452858
Purpose: Radiation-induced lung injury has been shown to alter regional ventilation and perfusion in the lung. However, changes in regional pulmonary gas exchange have not previously been measured. Methods And...
4.
Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N, et al.
J Natl Compr Canc Netw
. 2023 Nov;
21(11):1118-1131.
PMID: 37935098
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the...
5.
Erickson B, Cui Y, Ackerson B, Kelsey C, Yin F, Niedzwiecki D, et al.
Biomed Phys Eng Express
. 2023 Feb;
9(3).
PMID: 36827685
. Dose calculation in lung stereotactic body radiation therapy (SBRT) is challenging due to the low density of the lungs and small volumes. Here we assess uncertainties associated with tissue...
6.
Liveringhouse C, Latifi K, Asous A, Lam N, Rosenberg S, Dilling T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jan;
116(4):837-848.
PMID: 36657497
Purpose: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC). We aimed to...
7.
Subashi E, Feng L, Liu Y, Robertson S, Segars P, Driehuys B, et al.
Phys Imaging Radiat Oncol
. 2023 Jan;
25:100409.
PMID: 36655213
Background And Purpose: The accuracy and precision of radiation therapy are dependent on the characterization of organ-at-risk and target motion. This work aims to demonstrate a 4D magnetic resonance imaging...
8.
Raghunath S, Pfeifer J, Kelsey C, Nemani A, Ruhl J, Hartzel D, et al.
J Electrocardiol
. 2022 Nov;
76:61-65.
PMID: 36436476
Background: Several large trials have employed age or clinical features to select patients for atrial fibrillation (AF) screening to reduce strokes. We hypothesized that a machine learning (ML) model trained...
9.
Hoppe R, Advani R, Ai W, Ambinder R, Armand P, Bello C, et al.
J Natl Compr Canc Netw
. 2022 Apr;
20(4):322-334.
PMID: 35390768
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have...
10.
Zelenetz A, Gordon L, Chang J, Christian B, Abramson J, Advani R, et al.
J Natl Compr Canc Netw
. 2021 Nov;
19(11):1218-1230.
PMID: 34781267
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of...